Preformulation of FK506 prodrugs for improving solubility = FK506 프로드럭의 용해도를 개선한 제형

Cited 1 time in scopus
Metadata Downloads
Title
Preformulation of FK506 prodrugs for improving solubility = FK506 프로드럭의 용해도를 개선한 제형
Author(s)
Y G Na; H S Jun; D Kim; Byoung Chul Park; S K Lim; K H Lee; S J Hwang; J S Park; S H Jung; C W Cho
Bibliographic Citation
Bulletin of Korean Chemical Society, vol. 37, pp. 1313-1319
Publication Year
2016
Abstract
In order to improve water solubility of a lipophilic drug, tacrolimus (FK506), two prodrugs (FK506-G or FK506-S) such as FK506-M32-LS-G (FK506-G) and FK506-M32-LS-SL (FK506-S) were synthesized. Two prodrugs (FK506-G or FK506-S), including FK506, were characterized by differential scanning calorimetry (DSC), X-ray diffractometry (XRD), scanning electron microscopy (SEM), enzymatic kinetics, and cytotoxicity. A phase solubility test was conducted in distilled water, and the solubility of two prodrugs (FK506-G or FK506-S) was measured in various pH values for pH solubility profiles. Most interesting was that FK506-S showed the highest solubility, 866 μg/mL in water. In vitro enzymatic kinetics of two prodrugs (FK506-G or FK506-S) in human plasma was evaluated by measuring the decrease of FK506-G or FK506-S as well as the increase of FK506 by HPLC, and FK506-G or FK506-S was metabolized in 1 h in human plasma. Two prodrugs (FK506-G or FK506-S) including FK506 showed an IC50 of 336.6 μg/mL for FK506, 337.9 μg/mL for FK506-G, or 480.1 μg/mL for FK506-S against a conjunctive cell line, Clone 1-5c-4 cells. Taken together, FK506-S could be the most optimal prodrug for aqueous preparations based on preformulation data.
Keyword
CytotoxicityFK506PreformulationProdrugSolubility
ISSN
0253-2964
Publisher
Wiley
DOI
http://dx.doi.org/10.1002/bkcs.10861
Type
Article
Appears in Collections:
1. Journal Articles > Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.